# Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL

> **NCT03572634** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- CLL
- SLL
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** TP-0903
- **COMBINATION_PRODUCT:** TP-0903 and ibrutinib combination therapy

## Key facts

- **NCT ID:** NCT03572634
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-10
- **Primary completion:** 2020-01-21
- **Final completion:** 2020-01-21
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Given the extensive time projected to conclude the study hypothesis, it is no longer feasible to include this study of TP-0903.
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03572634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03572634, "Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03572634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*